The booming market for injectable peptides is drawing increasing scrutiny as Health and Human Services Secretary Robert F. Kennedy Jr. pushes to broaden access. These amino acid combinations, often sold as research chemicals not intended for human use, are fueling a gray-market frenzy that experts say is outpacing regulatory safeguards.
From collagen for skin to compounds promising muscle recovery and even facial relaxation, peptide products line store shelves. But online communities have taken it further, sourcing raw vials from dubious vendors and self-administering injections at home. The Hill found vendors using fake profiles and selling goods labeled “not for human consumption” while touting health benefits.
Google searches for “peptide” have skyrocketed, and Kennedy’s public enthusiasm—he called himself “a big fan” on The Joe Rogan Experience—has only intensified interest. In a recent hearing, Rep. David Kustoff (R-Tenn.) pressed Kennedy on his plans for “mainstreaming” these substances. Kennedy responded that peptides should be treated like supplements, not drugs, sidestepping FDA safety requirements for mass-marketed products with specific claims.
Regulatory Gray Zone
Peptides are protein fragments that act as signaling molecules. Some, like glutathione and GHK-Cu, are naturally occurring and touted for anti-aging effects. Others, such as BPC-157, have been studied for regenerative properties but lack rigorous human trials. “Most of these are not approved drugs,” said Edgar J. Asebey, a partner at Frier Levitt’s Life Science Group. “From the FDA regulatory world, that’s called an unapproved drug.”
The FDA classifies compounded peptides into three categories. Category 1 allows compounding for patients; Categories 2 and 3 are deemed unsafe or data-deficient. Shortly after Kennedy’s Rogan appearance, the FDA moved about a dozen peptides out of Category 2 into Category 1, potentially easing access through legitimate channels. Critics warn this could encourage risky self-medication.
Safety Concerns and Industry Pushback
Dr. David Lau, an obesity specialist at the University of Calgary, called Kennedy’s push “a real safety concern.” He noted that injectable peptides require proper dosing, injection technique, and side-effect monitoring. “Patients should really be counseled properly,” he said.
Jay Campbell, a longtime peptide advocate who sells guides and has a stake in Biolongevity Labs, argues peptides are distinct from drugs. “I don’t know any drugs that will accomplish what peptides will accomplish,” he said. But he cautioned they are “not magic bullets.”
The market’s growth mirrors broader trends in health optimization, but the lack of oversight raises parallels to other regulatory challenges, such as calls to redirect health dollars to patients ahead of 2026 reforms. Meanwhile, lawmakers are grappling with how to balance innovation and safety in an era of decentralized health choices.
As Kennedy pushes to expand peptide access, the gap between consumer enthusiasm and regulatory reality remains wide. For now, the gray market thrives, leaving patients to navigate a landscape where the line between therapy and risk is increasingly blurred.
